Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2-3
|
pubmed:dateCreated |
1995-6-29
|
pubmed:abstractText |
10 patients were subjected to tandem transplantation for breast cancer (n = 3), ovarian cancer (n = 2) and multiple myeloma (n = 5), at the Second Department of Medicine, Donauspital, Vienna. The breast cancer patients were in stages 2 and 3, respectively, at diagnosis and entered complete remission thereafter. 2 of them developed lymph node metastasis and additional local recurrence, the 3rd patient presented with distant metastasis. The 2 patients with ovarian cancer were in stages Figo III and IV, respectively, at the time of diagnosis, and showed minimal residual disease at second-look-operation. 5 patients with multiple myeloma were in stage 3 pretransplant. Peripheral stem cells were obtained after either high-dose cyclophosphamide or FEC induction and application of cytokines. In 4 patients, tandem transplantation has been completed. 1 patient with multiple myeloma, who had received total body irradiation in combination with chemotherapy for the 2nd transplant, succumbed from idiopathic interstitial pneumonia. No severe clinical complications were observed in all other patients. All patients with solid tumors entered complete remission after the 1st transplantation. 3 of them completed tandem transplantation. Of these, 2 remain in continuous complete remission, the 3rd patient relapsed in lymph nodes day 485. In patients who received only 1 course of high dose chemotherapy with stem cell transplantation, relapses occurred on days 29 and 75, respectively. All patients with multiple myeloma entered only partial remission. We conclude that supralethal chemotherapy with peripheral blood stem cell support is a safe procedure that may at least induce prolonged remissions in solid tumors and hematologic malignancies.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
ger
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0043-5341
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
145
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
41-4, 46-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7762251-Austria,
pubmed-meshheading:7762251-Breast Neoplasms,
pubmed-meshheading:7762251-Combined Modality Therapy,
pubmed-meshheading:7762251-Female,
pubmed-meshheading:7762251-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:7762251-Humans,
pubmed-meshheading:7762251-Male,
pubmed-meshheading:7762251-Middle Aged,
pubmed-meshheading:7762251-Multiple Myeloma,
pubmed-meshheading:7762251-Neoplasm Staging,
pubmed-meshheading:7762251-Ovarian Neoplasms,
pubmed-meshheading:7762251-Remission Induction,
pubmed-meshheading:7762251-Survival Rate,
pubmed-meshheading:7762251-Transplantation, Autologous
|
pubmed:year |
1995
|
pubmed:articleTitle |
[Tandem transplantation with peripheral autologous hematopoietic blood stem cells in treatment of oncologic and hematologic malignancies. Initial results of the Donauspital, Vienna].
|
pubmed:affiliation |
Ludwig-Boltzmann-Institut für Stammzelltransplantation, Wien.
|
pubmed:publicationType |
Journal Article,
English Abstract
|